|
|
Volumn 11, Issue 4, 2014, Pages 184-186
|
|
Haematological cancer: idelalisib-targeting PI3Kδ in patients with B-cell malignancies.
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CCL3 PROTEIN, HUMAN;
IDELALISIB;
MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA;
PHOSPHATIDYLINOSITOL 3 KINASE;
PIK3CD PROTEIN, HUMAN;
PIK3CD PROTEIN, MOUSE;
PROTEIN KINASE INHIBITOR;
PURINE DERIVATIVE;
QUINAZOLINONE DERIVATIVE;
TUMOR PROTEIN;
ANIMAL;
B CELL LYMPHOMA;
B LYMPHOCYTE;
CHEMICALLY INDUCED DISORDER;
CHRONIC LYMPHATIC LEUKEMIA;
CLINICAL TRIAL (TOPIC);
DIARRHEA;
DRUG ANTAGONISM;
DRUG EFFECT;
ENZYMOLOGY;
GENETICS;
HUMAN;
MOLECULARLY TARGETED THERAPY;
MOUSE;
MUTATION;
NOTE;
PHYSIOLOGY;
SECRETION (PROCESS);
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
TUMOR MICROENVIRONMENT;
ANIMALS;
ANTINEOPLASTIC AGENTS;
B-LYMPHOCYTES;
CHEMOKINE CCL3;
CLINICAL TRIALS AS TOPIC;
DIARRHEA;
HUMANS;
LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;
LYMPHOMA, B-CELL;
MICE;
MOLECULAR TARGETED THERAPY;
MUTATION;
NEOPLASM PROTEINS;
PHOSPHATIDYLINOSITOL 3-KINASES;
PROTEIN KINASE INHIBITORS;
PURINES;
QUINAZOLINONES;
SIGNAL TRANSDUCTION;
TREATMENT OUTCOME;
TUMOR MICROENVIRONMENT;
|
|
EID: 84908130105
PISSN: None
EISSN: 17594782
Source Type: Journal
DOI: 10.1038/nrclinonc.2014.42 Document Type: Note |
|
Times cited : (46)
|
|
References (0)
|
